Artara Therapeutics Inc TARA

$2.33 -0.11 (-4.51%)

Valuation

Market cap
137,691,000
Revenue TTM
$0
Net income TTM
$-57,440,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
867,500
Avg volume
1,075,628
Day's range
$2.28 – $2.47
Shares out
59,095,000
Stochastic %K
9%
Beta
1.47
Analysts
Strong Sell
Price target
$26.57

Price

Company profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an invest...

Show more

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
646 844 0337
Website
https://www.protaratx.com
Address
345 Park Avenue South, 3rd Floor, New York, United States

Latest news

Stocktwits

MaGo1981 Oct 26, 11:01 AM
$TARA daily news:
0 replies
Rocketman808 Oct 23, 12:34 PM
$TARA on the watchlist, will await lower entry
0 replies
pablo4 Oct 20, 5:40 PM
$TARA I am very bullish on TARA although I don't see any major price resurgence until spring of next year, most likely.....but what a great time to accumulate now while it's beaten down. Why? Well, how many small bios have a drug in their pipelines that has proven "curative?" TARA does with TARA-002 to treat LMs. To date, all data shows a curative effect. TARA owns global rights aside from Japan and Taiwan...TARA has responsibility to develop and commercialize TARA-002 globally while Chugai retains rights within Japan and Taiwan where the originator compound, OK-432 (Picibanil) is already approved and standard care for LMs. TARA is eligible for a valuable PRV upon approval of the BLA it intends to file in the 2nd half of 2027. I believe this BLA is going to be a major catalyst and cause a major increase in TARA's market cap. JMO
1 replies
Quantumup Oct 20, 10:48 AM
H.C. Wainwright reiterated $PVLA Buy-$246 after attending the 2026 PeDRA Annual Conference where Palvella presented new data. $NVS $TARA QNRX PFE Here's what H.C. Wainwright had to say: https://x.com/Quantumup1/status/2112495561437823246?s=20
0 replies
Bulldog1776 Oct 19, 9:56 PM
$TARA I have been following TARA for nearly two years now. At worst, this stock is a $4 a share stock. Once news comes out about the TARA-002 bladder cancer efficacy and safety, expected in Q4, this stock could and should zoom up to close to $10 a share. This is not a pipe dream. This is as close to true statement as one can make given the data and science behind the drug. $10 a share!
1 replies
pablo4 Oct 19, 1:18 AM
$TARA for those fretting the trading....my own opinion agrees with AI's explanation: probable catalysts behind this type of "newsless" price dislocation: • Institutional Tax-Loss Harvesting: Many mutual funds and institutional portfolios have fiscal year-ends on October 31. In the weeks leading up to this deadline, institutions frequently liquidate underperforming micro-cap positions to offset capital gains, creating severe downward pressure on high volume. • Forced Liquidation or Block Trades: In low-float, illiquid biotech stocks, a single large institutional holder exiting a position can quickly overwhelm the order book. Lacking sufficient buying liquidity, these large blocks trigger market-maker price reductions to absorb the shares. • Algorithmic and Stop-Loss Cascades: When a stock breaks through long-term psychological support levels, it often triggers systematic stop-loss orders and automated algorithmic short-selling, causing a self-reinforcing cascade of high-volume selling.
0 replies
Quantumup Oct 16, 3:55 PM
Raymond James reiterated $PVLA Strong Buy-$226 after Pavella's presentation of two posters at the 14th PeDRA Annual Conference. $NVS $TARA QNRX PFE Raymond James said -- The mLM analysis comparing the pediatric subgroups of patients aged 6-11 and 12-17 demonstrated significant and consistent reductions in lesion height, leaking/bleeding, and vesicle appearance from Qtorin rapamycin treatment across age groups after 168 days of treatment, and the cVM pediatric analysis demonstrated improvements in lesion severity and bleeding through week 24, with high treatment satisfaction. These data show that response to treatment at least trends toward being more favorable in the younger age groups, which is very supportive of a broad potential label for QTORIN rapamycin in both the mLM and cVM indications.
0 replies
Quantumup Oct 16, 2:48 PM
William Blair🏁 $PVLA and said -- We are initiating coverage of Palvella with an Outperform rating and DCF valuation of $266 per share. $NVS $TARA QNRX PFE Here's what William Blair went on to say in its initiation report: https://x.com/Quantumup1/status/2111106423593599304?s=20
0 replies